公开(公告)号：US11807642B2

公开(公告)日：2023-11-07

申请号：US17541682

申请日：2021-12-03

Applicant: Temple University—Of the Commonwealth System of Higher Education

Inventor： Benjamin E. Blass ,  Daniel J. Canney ,  Kevin M. Blattner

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US11319327B2

公开(公告)日：2022-05-03

申请号：US17015696

申请日：2020-09-09

Applicant: Temple University—Of The Commonwealth System of Higher Education ,  Praeventix, LLC

Inventor： Daniel J. Canney ,  Benjamin E. Blass ,  Kevin M. Blattner ,  Douglas A. Pippin

IPC: C07D491/107 ,  C07D221/00 ,  C07D295/073 ,  C07D309/08 ,  C07D493/10 ,  C07D513/04 ,  C07F7/10 ,  C07D413/10

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US11820774B2

公开(公告)日：2023-11-21

申请号：US17154761

申请日：2021-01-21

Applicant: Temple University—Of the Commonwealth System of Higher Education

Inventor： Benjamin E. Blass ,  Daniel J. Canney ,  Kevin M. Blattner

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

公开(公告)号：US20190367528A1

公开(公告)日：2019-12-05

申请号：US16349811

申请日：2017-11-15

Applicant: Temple University-Of The Commonwealth System of Higher Education ,  Praeventix, LLC

Inventor： Daniel J. Canney ,  Benjamin E. Blass ,  Kevin M. Blattner ,  Douglas A. Pippin

IPC: C07D491/107 ,  C07D221/00 ,  C07D309/08 ,  C07D493/10 ,  C07D513/04 ,  C07D295/073 ,  C07D413/10 ,  C07F7/10

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US20220306629A1

公开(公告)日：2022-09-29

申请号：US17054468

申请日：2019-05-10

Applicant: Temple University - Of The Commonwealth System of Higher Education

Inventor： Daniel J. Canney ,  Benjamin E. Blass ,  Kevin M. Blattner ,  Douglas A. Pippin

IPC: C07D471/10 ,  C07D487/04 ,  C07D401/06

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. A is selected from a group consisting of (group) and (group)

公开(公告)号：US11220505B2

公开(公告)日：2022-01-11

申请号：US16496065

申请日：2018-03-15

Applicant: Temple University-Of the Commonwealth System of Higher Education

Inventor： Benjamin E. Blass ,  Daniel J. Canney ,  Kevin M. Blattner

IPC: C07D487/04

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US10858368B2

公开(公告)日：2020-12-08

申请号：US16349811

申请日：2017-11-15

Applicant: Temple University—Of The Commonwealth System of Higher Education ,  Praeventix, LLC

Inventor： Daniel J. Canney ,  Benjamin E. Blass ,  Kevin M. Blattner ,  Douglas A. Pippin

IPC: C07D491/107 ,  C07D221/00 ,  C07D295/073 ,  C07D309/08 ,  C07D413/10 ,  C07D493/10 ,  C07D513/04 ,  C07F7/10

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US20230025932A1

公开(公告)日：2023-01-26

申请号：US17776531

申请日：2020-11-12

Applicant: Temple University-Of The Commonwealth System of Higher Education ,  Praeventix, LLC

Inventor： Daniel J. Canney ,  Benjamin Blass Blass ,  Kevin M. Blattner ,  Douglas A. Pippin

IPC: C07D491/107 ,  C07D405/06

Abstract: Described herein are new, selective modulators of the 5-HT7receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT7 modulator

公开(公告)号：US20220348581A1

公开(公告)日：2022-11-03

申请号：US17541682

申请日：2021-12-03

Applicant: Temple University-Of the Commonwealth System of Higher Education

Inventor： Benjamin E. Blass ,  Daniel J. Canney ,  Kevin M. Blattner

IPC: C07D487/04

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US20210238189A1

公开(公告)日：2021-08-05

申请号：US17015696

申请日：2020-09-09

Applicant: Temple University-Of The Commonwealth System of Higher Education ,  Praeventix, LLC

Inventor： Daniel J. Canney ,  Benjamin E. Blass ,  Kevin M. Blattner ,  Douglas A. Pippin

IPC: C07D491/107 ,  C07D221/00 ,  C07D295/073 ,  C07D309/08 ,  C07D413/10 ,  C07D493/10 ,  C07D513/04 ,  C07F7/10

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.